T cells as a therapeutic target in SLE. (April 2015)

• Record Type: Journal Article
• Authors: Comte, D; Karampetsou, M P; Tsokos, G C
• Other Names: Shoenfeld Yehuda guest-editor.
• Is Part Of: Lupus. Volume 24:Number 4/5(2015)
• Page Start: 351
• Page End: 363
• Publication Date: 2015-04
• Subjects: Systemic lupus erythematosus -- T cells -- interleukin-2 (IL-2) -- epigenetics -- treatment; Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1177/0961203314556139
• Languages: English
• ISSNs: 0961-2033

Abstract

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by a loss of tolerance to multiple endogenous antigens. SLE etiology remains largely unknown, despite recent insight into the immunopathogenesis of the disease. T cells are important in the development of the disease by amplifying the immune response and contributing to organ damage. Aberrant signaling, cytokine secretion, and tissue homing displayed by SLE T cells have been extensively studied and the underlying pathogenic molecular mechanisms are starting to be elucidated. T-cell-targeted treatments are being explored in SLE patients. This review is an update on the T-cell abnormalities and related therapeutic options in SLE.